Areerat Suputtitada, Supattana Chatromyen, Carl Pc Chen, David M Simpson
{"title":"全球卒中后痉挛干预措施的修订范围综述。","authors":"Areerat Suputtitada, Supattana Chatromyen, Carl Pc Chen, David M Simpson","doi":"10.1016/j.toxicon.2025.108311","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Stroke is a major global health concern, and post-stroke spasticity (PSS) can severely impair mobility and quality of life. This modified scoping review synthesizes the most current evidence up to 2024 for interventions targeting PSS, employing GRADE methodology and a packed bubble chart adapted from the Evidence Alert Traffic Light System to rigorously evaluate the state of evidence to assist global healthcare professionals and policymakers in developing context-sensitive strategies that are both effective and feasible within their specific healthcare environments.</p><p><strong>Methods: </strong>From a pool of 2,420 studies, 53 met our inclusion criteria and were subjected to a detailed analysis, representing 44 distinct interventions.</p><p><strong>Findings: </strong>In our findings, oral medications showed limited efficacy with potential adverse effects. Therefore, prioritizing GRADE A treatments with green traffic light like low-dose botulinum toxin type A (BoNT-A) injections, early intervention, and multimodal therapies of GRADE A can significantly reduce spasticity, as well as alleviate pain and shed light to enhance functional recovery. These treatments have a further advantage of requiring minimal therapy duration and personnel. Intrathecal baclofen (ITB) has demonstrated efficacy in managing severe spasticity following bilateral strokes, surpassing the effectiveness of oral medicines. Nevertheless, in settings with limited resources, therapies graded from A to C and indicated by green to yellow traffic lights can still be employed to control spasticity and accomplish rehabilitation goals, even though they require daily sessions that demand substantial time and personnel.</p><p><strong>Summary: </strong>Our study provides valuable insights into efficacious therapies for PSS and highlights areas requiring additional research to enhance clinical decision-making.</p>","PeriodicalId":23289,"journal":{"name":"Toxicon","volume":" ","pages":"108311"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Modified Scoping Review of Interventions for Global Post Stroke Spasticity.\",\"authors\":\"Areerat Suputtitada, Supattana Chatromyen, Carl Pc Chen, David M Simpson\",\"doi\":\"10.1016/j.toxicon.2025.108311\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Stroke is a major global health concern, and post-stroke spasticity (PSS) can severely impair mobility and quality of life. This modified scoping review synthesizes the most current evidence up to 2024 for interventions targeting PSS, employing GRADE methodology and a packed bubble chart adapted from the Evidence Alert Traffic Light System to rigorously evaluate the state of evidence to assist global healthcare professionals and policymakers in developing context-sensitive strategies that are both effective and feasible within their specific healthcare environments.</p><p><strong>Methods: </strong>From a pool of 2,420 studies, 53 met our inclusion criteria and were subjected to a detailed analysis, representing 44 distinct interventions.</p><p><strong>Findings: </strong>In our findings, oral medications showed limited efficacy with potential adverse effects. Therefore, prioritizing GRADE A treatments with green traffic light like low-dose botulinum toxin type A (BoNT-A) injections, early intervention, and multimodal therapies of GRADE A can significantly reduce spasticity, as well as alleviate pain and shed light to enhance functional recovery. These treatments have a further advantage of requiring minimal therapy duration and personnel. Intrathecal baclofen (ITB) has demonstrated efficacy in managing severe spasticity following bilateral strokes, surpassing the effectiveness of oral medicines. Nevertheless, in settings with limited resources, therapies graded from A to C and indicated by green to yellow traffic lights can still be employed to control spasticity and accomplish rehabilitation goals, even though they require daily sessions that demand substantial time and personnel.</p><p><strong>Summary: </strong>Our study provides valuable insights into efficacious therapies for PSS and highlights areas requiring additional research to enhance clinical decision-making.</p>\",\"PeriodicalId\":23289,\"journal\":{\"name\":\"Toxicon\",\"volume\":\" \",\"pages\":\"108311\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Toxicon\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.toxicon.2025.108311\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicon","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.toxicon.2025.108311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
A Modified Scoping Review of Interventions for Global Post Stroke Spasticity.
Purpose: Stroke is a major global health concern, and post-stroke spasticity (PSS) can severely impair mobility and quality of life. This modified scoping review synthesizes the most current evidence up to 2024 for interventions targeting PSS, employing GRADE methodology and a packed bubble chart adapted from the Evidence Alert Traffic Light System to rigorously evaluate the state of evidence to assist global healthcare professionals and policymakers in developing context-sensitive strategies that are both effective and feasible within their specific healthcare environments.
Methods: From a pool of 2,420 studies, 53 met our inclusion criteria and were subjected to a detailed analysis, representing 44 distinct interventions.
Findings: In our findings, oral medications showed limited efficacy with potential adverse effects. Therefore, prioritizing GRADE A treatments with green traffic light like low-dose botulinum toxin type A (BoNT-A) injections, early intervention, and multimodal therapies of GRADE A can significantly reduce spasticity, as well as alleviate pain and shed light to enhance functional recovery. These treatments have a further advantage of requiring minimal therapy duration and personnel. Intrathecal baclofen (ITB) has demonstrated efficacy in managing severe spasticity following bilateral strokes, surpassing the effectiveness of oral medicines. Nevertheless, in settings with limited resources, therapies graded from A to C and indicated by green to yellow traffic lights can still be employed to control spasticity and accomplish rehabilitation goals, even though they require daily sessions that demand substantial time and personnel.
Summary: Our study provides valuable insights into efficacious therapies for PSS and highlights areas requiring additional research to enhance clinical decision-making.
期刊介绍:
Toxicon has an open access mirror Toxicon: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. An introductory offer Toxicon: X - full waiver of the Open Access fee.
Toxicon''s "aims and scope" are to publish:
-articles containing the results of original research on problems related to toxins derived from animals, plants and microorganisms
-papers on novel findings related to the chemical, pharmacological, toxicological, and immunological properties of natural toxins
-molecular biological studies of toxins and other genes from poisonous and venomous organisms that advance understanding of the role or function of toxins
-clinical observations on poisoning and envenoming where a new therapeutic principle has been proposed or a decidedly superior clinical result has been obtained.
-material on the use of toxins as tools in studying biological processes and material on subjects related to venom and antivenom problems.
-articles on the translational application of toxins, for example as drugs and insecticides
-epidemiological studies on envenoming or poisoning, so long as they highlight a previously unrecognised medical problem or provide insight into the prevention or medical treatment of envenoming or poisoning. Retrospective surveys of hospital records, especially those lacking species identification, will not be considered for publication. Properly designed prospective community-based surveys are strongly encouraged.
-articles describing well-known activities of venoms, such as antibacterial, anticancer, and analgesic activities of arachnid venoms, without any attempt to define the mechanism of action or purify the active component, will not be considered for publication in Toxicon.
-review articles on problems related to toxinology.
To encourage the exchange of ideas, sections of the journal may be devoted to Short Communications, Letters to the Editor and activities of the affiliated societies.